Specialist speaks in favor of anti-VEGF with bimonthly regimen

LISBON, Portugal — Aflibercept, a designed molecule that can meet all expectations from the start of treatment, is the latest promising option in the treatment of age-related macular degeneration, according to one specialist. “It’s a fusion of the most high-affinity binding domains of the receptors and should provide higher affinity than ranibizumab (Lucentis, Genentech/Novartis) and bevacizumab (Avastin, Genentech/Roche) and even higher affinity than the VEGF binding to native receptors. Better than nature — that’s quite something,” Ursula Schmidt-Erfurth, MD, said at the Controversies in Ophthalmology meeting.